분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-02-01 15:40:10 , Hit : 593
 Shields Up for New Cancer Gene-Therapy Virus


GEN News Highlights
More »
January 31, 2018

https://www.genengnews.com/gen-news-highlights/shields-up-for-new-cancer-gene-therapy-virus/81255442/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20180131

The promise of gene therapy to treat cancer has always been limited by the vector used to deliver the rectified genetic payload. While off-targeting has always been a major concern, no less of an issue is the host immune system destroying the therapeutic virus before it has had a chance to complete its mission. Now, investigators at the University of Zurich (UZH) have developed a vector they believe will dramatically increase the efficiency of cancer gene therapy using human adenovirus 5. The findings from the new study were released today in Nature Communications, in an article entitled “Adenoviral Vector with Shield and Adapter Increases Tumor Specificity and Escapes Liver and Immune Control.”

There are innumerable different viruses that can be utilized for gene therapy efforts, but the human adenovirus 5, which normally causes the symptoms of a typical cold, has one substantial advantage: Its genome can be replaced completely by an artificial one that contains only "useful" genes. Without any of the viral genes left, the virus can no longer replicate and trigger diseases. In addition, the genome of the adenovirus is very large and does not integrate into human chromosomes.

Until recently, the use of adenoviruses in tumor therapy has been very limited. They lack the ability to infect cancer cells and therefore cannot inject the genetic blueprints for the therapeutic molecules to fight the disease. Moreover, adenoviruses are efficiently neutralized by the immune system and very rapidly eliminated by the liver. This new study shows how researchers succeeded in rebuilding these viruses so that they effectively recognize and infect tumor cells. "For this purpose, we have created molecules that act as an adapter between the virus and the tumor cell," explained lead study investigator Markus Schmid, Ph.D., professor in the department of biochemistry at the University of Zurich.

The adapters, which cling very tightly to the coat of the virus, can—depending on their version—bind to different surface molecules on the tumor cell. The scientists tested adapters for several receptors such as human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), which are present on several types of cancer cells. Only viruses equipped with these adapters could infect the tumor cells.

“[We engineered] a high-affinity protein coat, shielding the most commonly used vector in clinical gene therapy, human adenovirus type 5,” the authors wrote. “Using electron microscopy and crystallography we demonstrate a massive coverage of the virion surface through the hexon-shielding scFv fragment, trimerized to exploit the hexon symmetry and gain avidity. The shield reduces virion clearance in the liver. When the shielded particles are equipped with adaptor proteins, the virions deliver their payload genes into human cancer cells expressing HER2 or EGFR.”

The researchers subsequently hid the virus under a novel protein coat, which serves as camouflage for the virus and which protects it from the immune system. As a basis for this shield, the researchers used an existing antibody that they redesigned.

“When the shielded particles are equipped with adaptor proteins, the virions deliver their payload genes into human cancer cells expressing HER2 or EGFR,” the authors explained. “The combination of shield and adapter also increases viral gene delivery to xenografted tumors in vivo, reduces liver off-targeting and immune neutralization. Our study highlights the power of protein engineering for viral vectors overcoming the challenges of local and systemic viral gene therapies.”

Interestingly, the shield not only protects the redesigned virus from the immune cells but also prevents the virus from being eliminated by the liver, which normally quickly removes unmodified adenoviruses from the bloodstream, often making therapeutic applications impossible. With its shield and its adapter, these viral gene shuttles efficiently infected tumor cells in laboratory animals.

Using these stealth gene shuttles, the UZH scientists want to develop novel therapies for several types of cancer. The numerous advantages of adenoviruses will likely help to tackle one of the greatest problems of cancer medicine—the development of resistance against drugs.

"With this gene shuttle, we have opened up many avenues to treat aggressive cancers in the future, since we can make the body itself produce a whole cocktail of therapeutics directly in the tumor,” concluded senior study investigator Andreas Plückthun, Ph.D., director in the department of biochemistry at the University of Zurich.







1247   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 574
1246   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 576
1245   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 577
1244   Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 582
1243   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 587
  Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 593
1241   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 594
1240   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 600
1239   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 601
1238   CRISPR Enhancement Cures Genetic Disease in Mice  이성욱 2018/10/10 608
1237   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 608
1236   Second CRISPR-Modified Pregnancy May Be Underway  이성욱 2018/11/30 609
1235   Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 610
1234   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 612
1233   Scientists Doubt Results of CRISPR’d Embryos  이성욱 2017/09/02 615
1232   Human Genome Editing Committee Urges Halt in Germline Editing Trials  이성욱 2018/11/30 615
1231   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 620
1230   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 628
1229   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 639
1228   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 656

[1] 2 [3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN